Market Place
Sourcing Support
Oxford Biomedica Rebrands As OXB For CDMO Transformation
18 Sep 2024 //
GLOBENEWSWIRE
Oxford Biomedica Rebrands as OXB
18 Sep 2024 //
CONTRACT PHARMA
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
02 Sep 2024 //
GLOBENEWSWIRE
Oxford Biomedica to host a free webinar showcasing its AAV expertise
27 Aug 2024 //
GLOBENEWSWIRE
Oxford Biomedica – Half Year Trading Update and Notice of Interim Results
08 Aug 2024 //
GLOBENEWSWIRE
Oxford Biomedica Appoints Laurence Espinasse as Non-Executive Director
25 Jul 2024 //
PRESS RELEASE
Oxford Biomedica announces CFO transition
17 Jul 2024 //
GLOBENEWSWIRE
AAV Manufacturing Takes Center Stage at ASGCT24
07 May 2024 //
BIOSPACE
Preliminary results for the year ended 31 December 2023
29 Apr 2024 //
PRESS RELEASE
Oxford Biomedica Provides Update on CDMO Services Including New Comm Agreement
20 Mar 2024 //
PRESS RELEASE
Board changes following transformation to pure-play CDMO business model
11 Mar 2024 //
PRESS RELEASE
Update to Financial Guidance and 2023 Trading and Notice of Results
05 Mar 2024 //
GLOBENEWSWIRE
Oxford Biomedica completes acquisition of ABL Europe
29 Jan 2024 //
GLOBENEWSWIRE
Oxford Biomedica is hosting a free webinar to share clients success stories
23 Jan 2024 //
GLOBENEWSWIRE
Business Update
07 Dec 2023 //
GLOBENEWSWIRE
Oxford Biomedica pays €15M to acquire French CDMO ABL Europe
05 Dec 2023 //
FIERCE PHARMA
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux
04 Dec 2023 //
GLOBENEWSWIRE
Kyverna Therapeutics & Oxford Biomedica Sign Agreement for LentiVector® Platform
20 Sep 2023 //
PR NEWSWIRE
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
20 Sep 2023 //
GLOBENEWSWIRE
Oxford Biomedica pivots by laying off 200 people
20 Sep 2023 //
ENDPTS
Oxford Biomedica to host webinar showcasing the TetraVecta„¢ system
07 Sep 2023 //
GLOBENEWSWIRE
Kadans Expands Relationship with Oxford Biomedica
03 Jul 2023 //
CONTRACT PHARMA
Oxford Biomedica Publishes Journal Article On Novel Dual-Plasmid System
08 Jun 2023 //
GLOBENEWSWIRE
Oxford Biomedica launches TetraVecta - the next generation lentiviral vector
15 May 2023 //
GLOBENEWSWIRE
Oxford Biomedica Sol to Present Company Capabilities and its Platform at ASGCT
09 May 2023 //
GLOBENEWSWIRE
2023 AGM Notification
05 May 2023 //
PRESS RELEASE
2022 Annual Report and Accounts
28 Apr 2023 //
PRESS RELEASE
Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
26 Apr 2023 //
GLOBENEWSWIRE
Preliminary results for the year ended 31 December 2022
25 Apr 2023 //
PRESS RELEASE
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023
20 Feb 2023 //
GLOBENEWSWIRE
Oxford Biomedica forms new partnerships with three biotechnology companies
14 Dec 2022 //
GLOBENEWSWIRE
Oxford Biomedica Appoints Dr. Frank Mathias as CEO and Board Director
22 Nov 2022 //
CONTRACTPHARMA
Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer
22 Nov 2022 //
GLOBENEWSWIRE
Oxford Biomedica to complete sale &leaseback of Windrush Court facility for £60m
14 Nov 2022 //
GLOBENEWSWIRE
Amendment of Short-Term Loan Facility into new Term Loan Facility With Oaktree
07 Oct 2022 //
GLOBENEWSWIRE
Oxford Biomedica Solutions to Present Company Capabilities & Its Platform
05 Oct 2022 //
GLOBENEWSWIRE
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022
15 Sep 2022 //
GLOBENEWSWIRE
Oxford Biomedica Signs Licence & Supply Deal with New Partner for LentiVector
26 Jul 2022 //
GLOBENEWSWIRE
Oxford Biomedica initiates new project with Orchard Therapeutics
26 Jul 2022 //
GLOBENEWSWIRE
Oxford Biomedica expands Agreement with Juno Therapeutics
21 Jul 2022 //
OXB
Oxford Biomedica signs new deal to make AstraZeneca COVID shot
02 Jul 2022 //
REUTERS
2021 Annual report and accounts & AGM notification
27 Apr 2022 //
PRESS RELEASE
Oxford Biomedica shares plummet by 15% post British vaccine manufacturer warning
20 Apr 2022 //
THIS IS MONEY
Oxford Biomedica Preliminary Results
20 Apr 2022 //
GLOBENEWSWIRE
Oxford Biomedica Appoints Namrata P Patel as Non-Executive Director
13 Apr 2022 //
PRESS RELEASE
Oxford Biomedica broadens viral vector, launches Oxford Biomedica Solutions
11 Mar 2022 //
GLOBENEWSWIRE
Oxford Biomedica announces update to agreement with Sio Gene Therapies
31 Jan 2022 //
GLOBENEWSWIRE
Homology scratches cash itch with $130M deal to fund trials
29 Jan 2022 //
FIERCEBIOTECH
Virica Biotech Announces R&D Partnership With Oxford Biomedica
24 Jan 2022 //
BUSINESSWIRE
Oxford Biomedica Extends & Updates Commercial Supply Agreement with Novartis
13 Dec 2021 //
CONTRACTPHARMA
Oxford Biomedica in license and supply deals with Novartis and Arcellx
11 Dec 2021 //
UKNEWS
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class
19 Oct 2021 //
BUSINESSWIRE
Oxford Biomedica Announces that Boehringer has Exercised Option
19 Oct 2021 //
GLOBENEWSWIRE
Oxford BioMedica licences technology for cystic fibrosis treatment
18 Oct 2021 //
ISE
Russian spy `stole Oxford vaccine blueprint to use in Sputnik jab`
09 Oct 2021 //
IBC
Oxford sees new investment; Twist partners to help in discovery libraries
23 Sep 2021 //
ENDPTS
Oxford Biomedica gets $68.2M boost from India`s Serum
23 Sep 2021 //
FIERCEPHARMA
Oxford Biomedica Plc INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021
22 Sep 2021 //
GLOBENEWSWIRE
Oxford Biomedica sees interim revenues rocket as COVID-19 manufacturer Serum
21 Sep 2021 //
PROCTIVEINVESTOR
